Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07559474 · ClinicalTrials.gov registry record · Phase 1

A Study to Assess the Safety and Pharmacokinetics of INCB123667 When Administered Orally to Adult Participants With Moderate or Severe Hepatic Impairment

A Phase 1 study, sponsored by Incyte Corporation.

Recruiting
Registry status
Phase 1
Development phase
16
Enrollment target

NCT07559474: Recruiting Phase 1 study, sponsored by Incyte Corporation.

NCT07559474 is a Phase 1 study that is actively recruiting participants, run by Incyte Corporation. The registered enrollment target is 16 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (73% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07559474, a Phase 1 study, is actively recruiting participants, sponsored by Incyte Corporation.

RECRUITING
Registry status
Phase 1
Development phase
16 participants
Enrollment target

Study Summary

This study will be conducted to assess the safety and pharmacokinetics of INCB123667 when administered orally to adult participants with moderate or severe hepatic impairment.

Primary Outcome

Defined as the maximum plasma concentration.

Interventions

  • DRUG INCB123667

Trial Details

FieldValue
Enrollment Target 16 participants
Start Date 2026-05-27
Est. Completion 2027-04-13
Phase Phase 1
Incyte Corporation

239 total trials

What NCT07559474 shows while recruiting

NCT07559474 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 16 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (73% lower).

The record links to 0 conditions, and to 1 intervention - of which INCB123667 is the first listed.

NCT07559474 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT07559474 about?

NCT07559474 is a clinical study titled "A Study to Assess the Safety and Pharmacokinetics of INCB123667 When Administered Orally to Adult Participants With Moderate or Severe Hepatic Impairment". This study will be conducted to assess the safety and pharmacokinetics of INCB123667 when administered orally to adult participants with moderate or severe hepatic impairment.

What is the current status of trial NCT07559474?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 16 participants. The study started on 2026-05-27. Estimated completion is 2027-04-13.

What interventions are being tested in trial NCT07559474?

The interventions under investigation include: INCB123667 (DRUG).

Who is sponsoring clinical trial NCT07559474?

This trial is sponsored by Incyte Corporation, which has 239 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT07559474's enrollment target sits among peer trials

16 1786th of 2000 higher than 203 of 2,000 other Phase 1 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02422641 · 16 participants · Phase 2

    Prospective Evaluation Of High-Dose Systemic Methotrexate In Patients With Breast Cancer And Leptomeningeal Metastasis

  • NCT02851758 · 16 participants · NA

    Transplantation of Autologously Derived Mitochondria Following Ischemia

  • NCT03291028 · 16 participants

    Analysis of Primary and Metastatic Tumors in Patients With Renal Cell Carcinoma and Urothelial Carcinoma

  • NCT03425526 · 16 participants · Phase 1

    Donor T Cell Therapy in Treating Immunocompromised Patients With Adenovirus-Related Disease

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT07559474, the US trial registry maintained by the National Library of Medicine. NCT07559474 (small enrollment · none site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.